Aileron Therapeutics is a biopharmaceutical company focused on advancing a pipeline of first-in-class medicines for orphan pulmonary and fibrosis diseases. Aileron's lead product candidate, LTI-03, is a novel, synthetic peptide currently being evaluated in a Phase 1b clinical trial for the treatment of idiopathic pulmonary fibrosis. The company is dedicated to addressing significant unmet medical needs in orphan pulmonary and fibrosis indications.